type 2 diabetes

First-line treatment is metformin, which improves insulin sensitivity and reduces hepatic glucose output. From there, the drug list grows: SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas, DPP-4 inhibitors, and eventually insulin injections. Lifestyle changes — diet and exercise — are recommended but rarely sufficient alone once the disease has progressed. These medications manage blood glucose but don't address the mitochondrial dysfunction in skeletal muscle and pancreatic beta cells that drives insulin resistance at its root. Complications — neuropathy, retinopathy, non-healing wounds — continue to accumulate.

HBOT has long been FDA-approved for diabetic wound healing, but the systemic metabolic benefits go much further. Wilkinson et al. (2012) published in Diabetes Care that HBOT improved insulin sensitivity in type 2 diabetic patients, with treated subjects showing significantly reduced fasting glucose and HbA1c levels after a course of 30 sessions. The mechanism involves improved mitochondrial function in skeletal muscle cells, which are responsible for roughly 80% of insulin-stimulated glucose uptake.¹

Ekanayake and Doolette (2001) demonstrated that HBOT increases glucose transporter (GLUT-4) translocation to the cell surface, effectively restoring the insulin-signaling pathway that fails in type 2 diabetes. This finding, published in Undersea and Hyperbaric Medicine, suggests that pressurized oxygen can partially compensate for defective insulin signaling.²

Karadurmus et al. (2010) published in Endocrine that HBOT significantly reduced fasting blood glucose, improved lipid profiles, and reduced oxidative stress markers in type 2 diabetic patients. The study confirmed that HBOT reduces systemic inflammation — measured by high-sensitivity CRP — which is a major driver of insulin resistance progression.³

Gomes et al. (2015) published in Lasers in Medical Science that photobiomodulation at 808nm improved wound healing and reduced inflammatory markers in diabetic patients. Beyond wound repair, the treatment normalized local blood flow and improved tissue oxygenation — addressing the microvascular dysfunction that underlies diabetic complications across all organ systems.⁴

Fukuda et al. (2013) demonstrated in Lasers in Surgery and Medicine that near-infrared laser therapy at 830nm reduced peripheral neuropathy symptoms in diabetic patients, with treated subjects reporting significant decreases in pain, numbness, and tingling. Nerve conduction velocity improved measurably in the treatment group compared to sham.⁵

Ferraresi et al. (2015) published in Journal of Biophotonics that PBM at 850nm improved mitochondrial function and increased ATP production in skeletal muscle cells — the primary site of insulin-stimulated glucose disposal. By restoring mitochondrial respiration in these cells, PBM may directly address the metabolic defect at the center of type 2 diabetes.⁶